[1]俞邦,赵国桢,方晗语,等.口服中成药治疗小儿急性支气管炎的系统评价[J].西部中医药,2025,38(05):65-71.[doi:10.12174/j.issn.2096-9600.2025.05.13]
　YU Bang,ZHAO Guozhen,FANG Hanyu,et al.Systematic Assessment of Oral Chinese Patent Drug in the Treatment of Acute Bronchitis in Children[J].Western Journal of Traditional Chinese Medicine,2025,38(05):65-71.[doi:10.12174/j.issn.2096-9600.2025.05.13]
点击复制

口服中成药治疗小儿急性支气管炎的系统评价()
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
38
期数:
2025年05期
页码:
65-71
栏目:
二次研究
出版日期:
2025-05-15

文章信息/Info

Title:
Systematic Assessment of Oral Chinese Patent Drug in the Treatment of Acute Bronchitis in Children
作者:
俞邦1,2, 赵国桢3, 方晗语1,2, 冯沁祺1,2, 洪政1,2, 张洪春2
1.北京中医药大学，北京 100029
2.国家呼吸医学中心/呼吸和共病全国重点实验室/国家呼吸疾病临床研究中心/ 中国医学科学院呼吸病学研究院/中日友好医院中西医结合肺病一部，北京 100029
3.首都医科大学附属北京中医医院，北京 100010
Author(s):
YU Bang1,2, ZHAO Guozhen3, FANG Hanyu1,2, FENG Qinqi1,2, HONG Zheng1,2, ZHANG Hongchun2
1.Beijing University of Chinese Medicine, Beijing 100029, China
2.National Center for Respiratory Medicine/State Key Laboratory of Respiratory Health and Multimorbidity/ National Clinical Research Center for Respiratory Diseases/Institute of Respiratory for Pulmonary Diseases, Chinese Academy of Medical Sciences/Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China
3.Beijing Hospital of TCM Affiliated to Capital Medical University, Beijing 100010, China
关键词:
急性支气管炎; 小儿; Meta分析; 系统评价; 口服; 中成药
Keywords:
acute bronchitis;  children; Meta analysis; systematic review; oral; Chinese patent medicine
分类号:
R272
DOI:
10.12174/j.issn.2096-9600.2025.05.13
文献标志码:
A
摘要:
目的系统评价口服中成药治疗小儿急性支气管炎的有效性及安全性。 方法检索CNKI、万方、维普、CBM、Web of Science、EMbase、PubMed和The Cochrane Library，检索时间从建库之日至2021年12月9日，筛选口服中成药治疗小儿急性支气管炎的随机对照试验研究。采用Cochrane偏倚风险评估工具进行质量评价，使用RevMan 5.4软件进行Meta分析，对有效率进行试验序贯分析（trial sequential analysis，TSA），并根据GRADE标准进行证据质量评价。 结果共纳入随机对照试验26项，涉及患儿3236例。Meta分析结果显示：口服中成药联合西医常规疗法可以提高总有效率（RR=1.18，95%CI：1.15～1.21，P＜0.000 01），缩短止咳时间（MD=-1.55，95%CI：-2.06～-1.05，P＜0.000 01）、退热时间（MD=-1.11，95%CI：-1.40～-0.82，P＜0.000 01）、啰音消失时间（MD=-1.21，95%CI：-1.65～-0.76，P＜0.000 01）、咳痰消失时间（MD=-0.97，95%CI：-1.34～-0.60，P＜0.000 01），治疗后hs-CRP指标较对照组有所改善，差异均具有统计学意义，但不良反应率无明显差异。TSA结果提示口服中成药提高有效率的结论有稳定性。GRADE评价提示，总有效率为中质量证据，止咳时间、退热时间、啰音消失时间为极低质量证据。 结论口服中成药联合西医常规疗法治疗小儿急性支气管炎优于单纯西医常规治疗，但限于研究质量，相关结论有待进一步证实。
Abstract:
ObjectiveTo systematically evaluate the efficacy and safety of oral Chinese patent medicine in the treatment of acute bronchitis in children. MethodsRandomized controlled trials (RCTs) of oral Chinese patent medicine in the treatment of acute bronchitis in children were searched from CNKI, Wanfang, VIP, CBM, Web of Science, EMbase, PubMed and the Cochrane Library between the data of establishing the database and December 9, 2021. The quality was evaluated according to Cochrane Risk of Bias in Systematic Review, the Revman 5.4 software was used for meta-analysis, and the effective rate was tested by TSA, and the quality evaluation of the evidence was performed according to GRADE standards. ResultsThe study has included 26 RCTs and 3236 children. The results of Meta analysis showed that oral Chinese patent medicine combined with conventional therapy of Western medicine could improve total effective rate (RR=1.18, 95%CI:1.15 - 1.21, P<0.000 01), shorten the time of relieving the cough (MD=-1.55, 95%CI:-2.06 - -1.05, P<0.000 01), antipyretic time (MD=-1.11, 95%CI:-1.40 - -0.82, P<0.000 01), and the time of lung rale disappearance (MD=-1.21, 95%CI:-1.65 - -0.76, P<0.000 01), and the time of expectoration disappearance (MD=-0.97, 95%CI:-1.34 - -0.60, P<0.000 01), after the treatment, hs-CRP indexes have been improved compared with the control group, and the difference had statistical meaning, while no obvious difference was found in adverse reaction. TSA results suggested that the conclusion of oral Chinese patent medicine could enhance the effective rate has stability. GRADE evaluation indicated that total effective rate was the evidence of moderate quality, the time of relieving the cough, antipyretic time, and the time of lung rale disappearance were the evidences of very low quality. ConclusionOral Chinese patent medicine combined with conventional therapy of Western medicine is better than single Western medicine in the treatment of acute bronchitis in children, but limited to the research quality, the relevant conclusions need to be further confirmed.

相似文献/References:

[1]马腾.透穴疗法联合神经生长因子穴位注射治疗小儿麻痹性斜视50例临床观察[J].西部中医药,2012,25(12):92.
　MA Teng.Clinical Observation on Point-to-point Therapy and Point Injection of Nerve Growth Factor for 50 Cases of Infant Paralytic Strabismus[J].Western Journal of Traditional Chinese Medicine,2012,25(05):92.
[2]林海鸿.银翘散治疗手足口病的临床观察[J].西部中医药,2013,26(06):64.
　LIN Haihong.Clinical Observation on YinQiaoSan in Treating Hand-foot-and-mouth Disease[J].Western Journal of Traditional Chinese Medicine,2013,26(05):64.
[3]彭燕.中医辨证护理对小儿流行性腮腺炎临床疗效的影响[J].西部中医药,2013,26(08):122.
　PENG Yan.TCM Nursing for Children with Mumps[J].Western Journal of Traditional Chinese Medicine,2013,26(05):122.
[4]贡保吉.藏西医结合治疗小儿支气管肺炎50例疗效观察[J].西部中医药,2013,26(10):65.
　GONG Baoji.Observation on the Combination of Tibetan and Western Medicine in Treating 50 Cases of Bronchopneumonitis in Children[J].Western Journal of Traditional Chinese Medicine,2013,26(05):65.
[5]扈志银.射干麻黄汤化裁佐治小儿毛细支气管炎 35 例[J].西部中医药,2014,27(08):55.
[6]张学军.护理干预在小儿重症肺炎并发呼吸衰竭中的临床作用[J].西部中医药,2014,27(08):134.
[7]柳树英,杨志华,原睿,等.微生态制剂与肠道菌群平衡观在小儿腹泻中的应用[J].西部中医药,2014,27(12):94.
[8]兰昌梅,王明明△.小儿咳嗽从脾论治的研究进展[J].西部中医药,2015,28(02):135.
[9]任耀全,石宗珂,沈玉鹏.麻杏化瘀汤加减治疗肺炎喘嗽痰热闭肺型疗效观察[J].西部中医药,2015,28(05):103.
[10]张晓春,王媛媛,李志锋,等.壮医药线背穴点灸治疗小儿外感发热100例[J].西部中医药,2015,28(06):67.[doi:2015/6/16 0:00:00]

备注/Memo

备注/Memo:
俞邦（1999—），男，在读硕士研究生。研究方向：肺系疾病的中医诊治。国家重点研发计划中医药现代化研究重点专项（2019YFC1712003）；中医药传承与创新“百千万”人才工程（岐黄工程）（2019-QTL-003）。
更新日期/Last Update: 2025-05-15